Sign in
GH Stock Price, Chart, Stats & News
Guardant Health, Inc.
Save
18.16B
Market cap
–
Current P/E
–
Forward P/E
GH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 64.46% |
Operating margin | -44.53% |
Pretax margin | -42.52% |
Net margin | -42.39% |
Effective tax rate | 0.30% |
ROA | -20.67% |
ROE | 164.85% |
D/E | -16.94x |
Interest coverage ratio | -112.20x |
GH valuation
P/E | – |
P/S | 11.30x |
P/B | -109.62x |
P/CF | -63.12x |
P/FCF | -50.27x |
P/OCF | -63.12x |
PEG | 8.39x |
EV multiple | -26.19x |
About
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients.
Similar securities
Based on sector and market capitalization
Report issue